Sodium Pyruvate Treatment for Hyperkeratotic Disorders

Sb, Levy; Goldsmith, Lowell A.

doi:10.1097/00007611-197903000-00022

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 15 , 16 Clinically, sodium pyruvate has a good safety profile and has been given to patients for a variety of disorders ranging from Friedreich's ataxia 17 to open heart operations. 18 It has been administered via several routes, including intravenous, 18 topical administration, 19 dietary supplementation, 20 and intranasally. 15 , 16 The purpose of the five studies presented here was to test the therapeutic value of sodium pyruvate to improve nasal inflammation in patients with AR.…”

Section: Introductionmentioning

confidence: 99%

Sodium Pyruvate Nasal Spray Reduces the Severity of Nasal Inflammation and Congestion in Patients with Allergic Rhinitis

Martin¹,

Lupfer

Amen³

2022

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

Background: As an anti-inflammatory and antioxidant, sodium pyruvate significantly reduces inflammatory cytokines and oxygen radicals such as interleukin (IL) IL-6, IL-8, Monocyte Chemoattractant Protein-1, and hydrogen peroxide. Thus, sodium pyruvate holds promise as a treatment for many respiratory diseases, including allergic rhinitis (AR). Novel treatments for AR are needed as current medications, including steroids, often fail to treat severe symptoms. Methods: The data from five human clinical studies were analyzed to determine the effect of 20 mM sodium pyruvate nasal spray (N115) in patients with AR. Nasal inflammation scores were compared to a placebo control or a no-treatment baseline control. Three studies were open-labeled and two were appropriately blinded to both patients and clinicians using computer randomization of subjects. Results: The intranasal administration of sodium pyruvate significantly improved nasal inflammation scores in all five clinical trials of patients with AR ( p < 0.0001 in all trials). Conclusions: These results give credence to the overall ability of sodium pyruvate, administered by nasal spray, to treat inflammation of the nasal airways.

show abstract

Section: Introductionmentioning

confidence: 99%

Sodium Pyruvate Nasal Spray Reduces the Severity of Nasal Inflammation and Congestion in Patients with Allergic Rhinitis

Martin¹,

Lupfer

Amen³

2022

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Clinically, sodium pyruvate has been given to patients for a variety of disorders ranging from Friedreich's ataxia (13) to open heart operations. (14)(15)(16)(17) It has been administered via several parenteral routes including intravenous, (15) topical administration for hyperkeratotic disorders, (16) and in dietary supplementation. (17) Inhalation delivery of pyruvate for lung disease has not been reported.…”

Section: Introductionmentioning

confidence: 99%

Inhaled Sodium Pyruvate Improved FEV₁and Decreased Expired Breath Levels of Nitric Oxide in Patients with Chronic Obstructive Pulmonary Disease

Votto

Bowen

Barton

et al. 2008

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

Exogenously administered sodium pyruvate has a variety of biological effects including antioxidant/anti-inflammatory effects. Chronic obstructive pulmonary disease (COPD) is an inflammatory disease of the airways mediated in part by reactive oxygen species (ROS) and reactive nitrogen species (RNS). The current therapies for COPD have limited efficacy. This study was designed to test the safety and therapeutic efficacy of inhaled pyruvate in COPD patients. Subjects were randomized to receive either sodium pyruvate or placebo three times per day over a 6-week period. Long-term efficacy was evaluated by spirometry and expired breath nitric oxide (NO) levels taken at baseline, 3 days, 1 week, 2 weeks, 4 weeks, and 6 weeks. In addition, acute assessments (1 h pre- and 1 h postinhalation of compound) were made at day 0 and at 4 weeks. Subjects receiving inhaled pyruvate showed significant (p < 0.02) improvement of approximately 11% in forced expiratory volume in 1 sec (FEV(1)) at 6 weeks, whereas subjects receiving placebo did not. The inhalation of pyruvate or placebo had no significant effect on expired breath NO levels at any of the long-term outcome time points; measurements were made 12 h after the last inhalation of the compound. In contrast, acute assessments (1 h pre-and 1 h postinhalation of compound) of expired breath NO made at 4 weeks demonstrated that inhalation of pyruvate resulted in a significant (p

show abstract

„Keratolytische“ und komedogene Wirkung

Gloor

1982

Pharmakologie Dermatologischer Externa

View full text Add to dashboard Cite

Sodium Pyruvate Treatment for Hyperkeratotic Disorders

Cited by 4 publications

References 0 publications

Sodium Pyruvate Nasal Spray Reduces the Severity of Nasal Inflammation and Congestion in Patients with Allergic Rhinitis

Sodium Pyruvate Nasal Spray Reduces the Severity of Nasal Inflammation and Congestion in Patients with Allergic Rhinitis

Inhaled Sodium Pyruvate Improved FEV₁and Decreased Expired Breath Levels of Nitric Oxide in Patients with Chronic Obstructive Pulmonary Disease

„Keratolytische“ und komedogene Wirkung

Contact Info

Product

Resources

About

Sodium Pyruvate Treatment for Hyperkeratotic Disorders

Cited by 4 publications

References 0 publications

Sodium Pyruvate Nasal Spray Reduces the Severity of Nasal Inflammation and Congestion in Patients with Allergic Rhinitis

Sodium Pyruvate Nasal Spray Reduces the Severity of Nasal Inflammation and Congestion in Patients with Allergic Rhinitis

Inhaled Sodium Pyruvate Improved FEV1and Decreased Expired Breath Levels of Nitric Oxide in Patients with Chronic Obstructive Pulmonary Disease

„Keratolytische“ und komedogene Wirkung

Contact Info

Product

Resources

About

Inhaled Sodium Pyruvate Improved FEV₁and Decreased Expired Breath Levels of Nitric Oxide in Patients with Chronic Obstructive Pulmonary Disease